NCT name | Arm | Primary endpoint | Results |
---|---|---|---|
NCT00903175 RECORD 3 | First-line Everolimus followed by second line sunitinib vs First line sunitinib followed by second line everolimus | PFS | Median PFS 21.7 months (mo.) (95%CI: 15.1–26.7) vs 22 mo. (95%CI16–29.8). Median OS: 22.4 mo. (95%CI 18.6–33.3 Vs 29.5 mo. (95% CI:22.8–33.1) |
NCT00720941 COMPARZ | Control arm: Sunitinib Experimental arm: Pazopanib | PFS | HR: 1.05 95% CI: 0.90 to 1.22 OS: HR: 0.91,95% CI: 0.76–1.08 |
NCT00073307 TARGET | Experimental arm: Sorafenib Placebo comparator: Placebo | OS | Median PFS: 5.5mo. vs 2.8mo. HR 0.44 95% CI 0.35–0.55 p < 0.01. First interim analysis of OS: sorafenib reduced the risk of death (HR: 0.72; 95%CI, 0.54–0.95 P = 0.02) |
NCT02231749 CheckMate 214 | Experimental arm: Nivolumab + Ipilumab Active comparator: Sunitinib | ORR, OS, PFS | 18 month OS: 75% (95%CI-70 to 78) vs 60% (95%CI: 55–65); ORR: 42% vs 27%, median PFS 11.6mo. vs 8.4 mo. |
NCT01835158 Cabosun | Arm 1: Cabozantinib Arm 2: Sunitinib | PFS, OS | Median PFS 8.2 vs 5.6 mo. adjusted HR, 0.66; 95% CI, 0.46 to 0.95 P = 0.012 ORR 33% vs 12% |
NCT02684006 Javelin Renal 101 | Experimental: Avelumab plus axitinib Active comparator: Sunitinib | PFS, OS | Median PFS 13.8mo vs. 7.2 mo.HR 0.61 95% confidence interval [CI], 0.47 to 0.79; P < 0.001, ORR 55.2% vs. 25.5% |
NCT02853331 KEYNOTE426 | Experimental: Pembrolizumab + Axitinib Active comparator: Sunitinib | PFS, OS | Median PFS: 15.1 mo. vs. 11.1mo. HR: 0.69; 95% CI, 0.57 to 0.84; P < 0.001 ORR: 59.3% (95% CI, 54.5 to 63.9) vs. 35.7% (95% CI, 31.1 to 40.4) |